Pulling SEC filings + quote and writing the call…

Key statistics

Valuation

Enterprise value$14.9M

EV / EBITDA—

EV / Sales—

EV / FCF—

P / FCF—

PEG (trailing)—

Earnings yield—

FCF yield—

Quality & risk

ROIC (est.)—

Free cash flow—

Total debt—

Net cash$25.7M

Capital returns

Buyback yield—

Dividend yield (est.)—

Shareholder yield—

Shares Δ YoY+28.1%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Frequently asked

Is Genenta Science S.p.A. (GNTA) a buy?

GNTA currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Mixed signals in the latest filings.

What is Genenta Science S.p.A.'s quality score?

GNTA scores 29.75484381178331/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

GNTA

Genenta Science S.p.A.

Sell

$1.72

▼ -4.44%

$1.72▼ -44.52%

over 1Y

L $0.58H $6.20

Today-4.4%

1W-0.6%

1M-21.8%

3M+142.3%

YTD+22.0%

1Y-44.5%

Sell

Conviction

Horizon

Medium (3–12mo)

Street · 7 analysts

Buy

Mixed signals in the latest filings.

Genenta Science S.p.A. shows limited reported revenue.

On these fundamentals, GNTA screens as SELL on the SEC figures.

Financials · annual, by fiscal year

No income data filed.

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value$14.9M

EV / EBITDA—

EV / Sales—

EV / FCF—

P / FCF—

PEG (trailing)—

Earnings yield—

FCF yield—

Quality & risk

ROIC (est.)—

Free cash flow—

Total debt—

Net cash$25.7M

Capital returns

Buyback yield—

Dividend yield (est.)—

Shareholder yield—

Shares Δ YoY+28.1%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Recent news

market news →

Pre Market Movers: GNTA, HCWC, ZCMD Set The PathBullish

nasdaq.com· 2026-06-01

Weekly Buzz: SNY, REGN Get FDA Nod; It's A No For ABBV, GRCE; LLY Acquires KeloniaBullish

nasdaq.com· 2026-04-24

Genenta, evolving into Saentra Forge, has signed a Binding Offer with Sòphia High Tech, an Italian company manufacturing critical parts for Europe's space and defense programsBullish

globenewswire.com· 2026-03-27

Genenta, evolving into Saentra Forge, continues to evaluate strategic options for its original biotechnology platform derived from the research of Professor Luigi NaldiniBullish

globenewswire.com· 2026-03-24

Genenta Science SPA (GNTA) Shifting from Biotech to Defense BusinessBullish

finance.yahoo.com· 2026-02-28

Genenta Announces Strategic Transformation into a Biotech, Defense, Aerospace, and National Security Industrial ConsolidatorBullish

globenewswire.com· 2026-01-27

Recent filings

all on EDGAR ↗

Frequently asked

Is Genenta Science S.p.A. (GNTA) a buy?: GNTA currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Mixed signals in the latest filings.
What is Genenta Science S.p.A.'s quality score?: GNTA scores 29.75484381178331/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

Sources: SEC EDGAR (CIK 0001838716, latest 6-K filed 2026-07-01) · EODHD · as of 7/4/2026, 4:53:07 AM.

Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.